Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07803783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy

Name: A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy — clinical trial record (NCT07803783)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorMediLink Therapeutics (Suzhou) Co., Ltd.

Started2026-10

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer patients who have failed prior Gemcitabine-based systemic therapy.

Trial Details

NCT Number	NCT07803783
Lead Sponsor	MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions	Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment	320 participants
Start Date	2026-10
Primary Completion	2029-01 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-04